Tag: romosozumab
Romosozumab receives approval in Japan for treatment of osteoporosis in patients...
The Japanese Ministry of Health, Labor and Welfare has granted a marketing authorisation for EVENITY (romosozumab; Amgen and UCB) for the treatment of osteoporosis...
FDA advisory committee to review Evenity (romosozumab) for the treatment of...
The US Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) are to review data supporting the Biologics License Application...
Romosozumab leads to significant bone mineral density gains at lumbar spine...
UCB and Amgen have announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in...